5. Dieguez H.H., Romeo H.E., Alaimo A. (2019) Oxidative Stress Damage Circumscribed to the central Temporal Retinal Pigment Epithelium in Early Experimental Non-exudative Age-Related Macular Degeneration. FreeRadic.Biol.Med., vol. 131, pp. 72-80.
6. Rolle T., Ponzetto A., Malinverni L. (2021) The Role of Neuroinflammation in Glaucoma: An Update on Molecular Mechanisms and New Therapeutic Options. Front Neurol., vol. 11, p. 612422.
7. Fu L., Kwok S.S., Chan Y.K., Ming Lai J.S., Pan W. (2019) Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications. BioMedresearch international, 8397521.
8. Conti F., Romano G.L., Eandi C.M., Toro M.D., Rejdak R. (2021) Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage. Frontiers in pharmacology, vol. 12, 705405.
9. Secades Julio J. (2021) Role of Citicoline in the Management of Traumatic Brain Injury. Pharmaceuticals, vol. 14, no 5, p. 410.
10. Bucolo C., Leggio G.M., Drago F. (2019) Dopamine outside the brain: The eye, cardiovascular system and endocrine pancreas. Pharmacol Ther., vol. 203, p. 107392.
11. Faiq M.A., Wollstein G., Schuman J.S. (2019) Cholinergic nervous system and glaucoma: From basic science to clinical applications. Prog. Retin. Eye Res., vol. 72, p. 100767.
12. Mйlik Parsadaniantz S., Rйaux-le Goazigo A., Sapienza A. (2020) Glaucoma: A Degenerative Optic Neuropathy Related to Neuroinflammation? Cells, vol. 9, no 3, p. 535.
13. Gilgun-Sherki Y, Melamed E., Offen D. (2001) Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology, vol. 40, no 8, pp. 959-975.
14. Cammalleri M., Dal Monte M., Amato R., Bagnoli P, Rusciano D. (2020) A Dietary Combination of Forskolin with Homotaurine, Spearmint and B Vitamins Protects Injured Retinal Ganglion Cells in a Rodent Model of Hypertensive Glaucoma. Nutrients, vol. 12, no 4, p. 1189.
15. Tezel G. (2021) Multifactorial Pathogenic Processes of Retinal Ganglion Cell Degeneration in Glaucoma towards Multi-Target Strategies for Broader Treatment Effects. Cells, vol. 10, no 6, p. 1372.
16. Parisi V., Oddone F., Ziccardi L. (2018) Citicoline and retinal ganglion cells: effects on morphology and function. Curr Neuropharmacol., vol. 16, pp. 919-932.
17. Gandolfi S., Marchini G., Caporossi A. (2020) Cytidine 5'-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. Nutrients, vol. 12, p. 793.
18. Roberti G., Tanga L., Michelessi M. (2015) Cytidine 5'-Diphosphocholine (Citicoline) in glaucoma: Rationale of its use, current evidence and future perspectives. Int. J. Mol. Sci., vol. 16, pp. 28401-28417.
19. Flaxman S.R., Bourne R.R.A., Resnikoff S. (2017) Global causes of blindness and distance vision impairment 1990-2020: A systematic review and meta-analysis. Lancet Glob. Health., vol. 5: e1221-e1234.
20. Tham Y.C., Li X., Wong T.Y., Quigley H.A. (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology, vol. 21, no 11, pp. 2081-2090.
21. Williams P.A., Harder J.M., Foxworth N.E. (2017) Vitamin B-3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science, vol. 355, pp. 756-760.
22. Berry R.H., Qu J., John S.W.M. (2015) Synapse loss and dendrite remodeling in a mouse model of glaucoma. PLoS One, vol. 10: e0144341.
23. Della Santina L., Inman D.M., Lupien C.B. (2013) Differential progression of structural and functional alterations in distinct retinal ganglion cell types in a mouse model of glaucoma. JNeurosci, vol. 33, pp. 17444-17457.
24. Williams P.A., Howell G.R., Barbay J.M. (2013) Retinal ganglion cell dendritic atrophy in DBA/2J glaucoma. PLoS One, vol. 8: e72282.
25. Singh A., Kukreti R., Saso L. (2019) Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules, vol. 24, p. 1583.
26. Casson R.J., Chidlow G., Crowston J.G. (2020) Retinal energy metabolism in health and glaucoma. Prog. Retin. Eye Res., 100881. doi: 10.1016/j. preteyeres.2020.100881.
27. Chou T.H., Porciatti V. (2020) Adaptable retinal ganglion cell function: assessing autoregulation of inner retina pathways. Neural Regen Res., vol. 15, no 12, pp. 2237-2238.
28. Wan P, Long E., Li Z. (2021) TET-dependent GDF7 hypomethylation impairs aqueous humor outflow and serves as a potential therapeutic target in glaucoma. Mol Ther., vol. 29, no 4, pp. 1639-1657.
29. Zhu Y., Pappas A.C., Wang R. (2018) Ultrastructural Morphology of the Optic Nerve Head in Aged and Glaucomatous Mice. Invest Ophthalmol Vis Sci., vol. 59, no 10, pp. 3984-3996.
30. Reinehr S., Koch D., Weiss M. (2019) Loss of retinal ganglion cells in a new genetic mouse model for primary open-angle glaucoma. J Cell Mol Med, vol. 23, no 8, pp. 5497-5507.
31. Zhou T., Souzeau E., Sharma S. (2017) Whole exome sequencing implicates eye development, the unfolded protein response and plasma membrane homeostasis in primary open-angle glaucoma. PLoS One., vol. 12, no 3, e0172427.
32. Rusciano D., Pezzino S., Mutolo M.G. (2017) Neuroprotection in glaucoma: Old and new promising treatments. Adv. Pharmacol. Sci., 4320408. doi: 10.1155/2017/4320408.
33. He S., Stankowska D.L., Ellis D.Z. (2018) Targets of Neuroprotection in Glaucoma. J Ocul Pharmacol Ther., vol. 34, no 1-2, pp. 85-106.
34. Rossetti L., lester M., Tranchina L. (2020) Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial. J. Glaucoma, vol. 29, pp. 513-520.
35. Yang H., Reynaud J., Lockwood H. (2017) The connective tissue phenotype of glaucomatous cupping in the monkey eye - Clinical and research implications. Prog Retin Eye Res., vol. 59, pp. 1-52.
36. Kunimi H., Miwa Y., Katada Y. (2019) HIF inhibitor topotecan has a neuroprotective effect in a murine retinal ischemia-reperfusion model. PeerJ., vol. 7, e7849.
37. Zheng F., Zhang Q., Shi Y. (2019) Age-dependent Changes in the Macular Choriocapillaris of Normal Eyes Imaged With Swept-Source Optical Coherence Tomography Angiography. Am J Ophthalmol., vol. 200, pp. 110-122.
38. Khramenko N.I., Konovalova N.V., Guzun O.V. (2018) Regional and central hemodynamics in ischemic optic neuropathy. J.ophthalmol. (Ukraine), no 3, pp. 3-9.
39. Almasieh M., Catrinescu M.M., Binan L. (2017) Axonal Degeneration in Retinal Ganglion Cells Is Associated with a Membrane Polarity-Sensitive Redox Process. J Neurosci, vol. 37, pp. 3824-3839.
40. Petty H.R. (2018) Frontiers of Complex Disease Mechanisms: Membrane Surface Tension May Link Genotype to Phenotype in Glaucoma. Front Cell Dev Biol., vol. 6, p. 32.
41. Risner M.L., Pasini S., Cooper M.L. (2018) Axogenic mechanism enhances retinal ganglion cell excitability during early progression in glaucoma. Proc Natl Acad Sci USA, vol. 115, E2393-E2402.
42. Munemasa Y., Kitaoka Y., Kuribayashi J. (2010) Modulation of mitochondria in the axon and soma of retinal ganglion cells in a rat glaucoma model. JNeurochem., vol. 115, pp. 1508-1519.
43. Guzun O.V., Khramenko N.I., Konovalova N.V. (2021) Long-term neuroprotection of the optic nerve after toxic injury with methanol (experimental and clinical observations). Ophthalmology. Eastern Europe, vol. 11, no 4, pp. 566-580.
44. Bucolo C., Platania C.B.M., Drago F. (2018) Novel Therapeutics in Glaucoma Management. Curr. Neuropharmacol., vol. 16, pp. 978-992.
45. Virno M., Pecori-Giraldi J., Liguori A. (2020) The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). Acta Ophthalmol. Scand., vol. 232, pp. 56-57.
46. Lanza M., Gironi Carnevale U.A., Mele L. (2019) Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study with a 2-Year Follow-Up. Front. Pharmacol., vol. 10, p. 1117.
47. Ottobelli L., Manni G.L., Centofanti M. (2013) Citicoline oral solution in glaucoma: Is there a role in slowing disease progression? Ophthalmologica, vol. 229, pp. 219-226.
48. Parisi V. (2005) Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5'-diphosphocholine (citicoline): A study of 8 years of follow-up. Doc. Ophthalmol., vol. 110, pp. 91-102.
49. Parisi V., Coppola G., Centofanti M. (2008) Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog. Brain Res., vol. 173, pp. 541-554.
50. Parisi V., Coppola G., Ziccardi L. (2008) Cytidine-5'-diphosphocholine (Citicoline): A pilot study in patients with non-arteritic ischaemic optic neuropathy. Eur. J. Neurol., vol. 15, pp. 465-474.
51. Parisi V., Barbano L., Di Renzo A. (2019) Neuroenhancement and neuroprotection by oral solution citicoline in nonarteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study. PLoS ONE, vol. 14, e0220435.
52. Parravano M., Scarinci F., Parisi V. (2020) Citicoline and Vitamin B(12) Eye Drops in Type 1 Diabetes: Results of a 3-year Pilot Study Evaluating Morpho-Functional Retinal Changes. Adv. Ther., vol. 37, pp. 1646-1663.
53. Chitnis T., Weiner H.L. (2017) CNS inflammation and neurodegeneration. J Clin Invest., vol. 127, pp. 3577-3587.
54. Dias C., Nita E., Faktor J. (2021) CHIP-dependent regulation of the actin cytoskeleton is linked to neuronal cell membrane integrity. Science, vol. 24, no 8, p. 102878.
55. Munzberg H., Qualls-Creekmore E., Berthoud H.R., Morrison C.D., Yu S. (2016) Neural Control of Energy Expenditure. Handb Exp Pharmacol., vol. 233, pp. 173-194.
56. Qadri R., Goyal V., Behari M. (2021) Alteration of Mitochondrial Function in Oxidative Stress in Parkinsonian Neurodegeneration: A CrossSectional Study. Ann Indian Acad Neurol., vol. 24, no 4, pp. 506-512.
57. World Health Organization (2021) Available at: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health (accessed20 March 2021)
58. Van der Merwe Y, Murphy M.C., Sims J.R. (2021) Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure- Independent Control. Neurotherapeutics, Apr 13. doi: 10.1007/s13311-021-01033-6.
59. Perusek L., Maeda T. (2013) Vitamin A derivatives as treatment options for retinal degenerative diseases. Nutrients, vol. 5, no 7, pp. 2646-2666.
60. Petrovic S., Arsic A., Ristic-Medic D. (2020) Lipid peroxidation and antioxidant supplementation in neurodegenerative diseases: a review of human studies. Antioxidants (Basel, Switzerland), vol. 9, p. 128.
61. Carr A., Maggini S. (2017) Vitamin C and immune function. Nutrients, vol. 9, p. 1211.
62. Mikkelsen K., Apostolopoulos V. (2018) B vitamins and ageing. SubcellBiochem., vol. 90, pp. 451-470.
63. Rivlin R.S. (2007) Riboflavin (Vitamin B2). Handbook of Vitamins. 4th ed. CRC Press; Boca raton, FL, USA, pp. 233-252.
64. Tribble J.R., Otmani A., Sun S. (2021) Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction. Redox Biol., vol. 43: e101988.
65. Williams P.A., Harder J.M., Cardozo B.H. (2018) Nicotinamide treatment robustly protects from inherited mouse glaucoma. Commun IntegrBiol., vol. 11: e1356956.
66. Hui F., Tang J., Williams P.A. (2020) Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial. Clin Exp Ophthalmol., vol. 48, pp. 903-914.
67. McAllister B.B., Dyck R.H. (2017) Zinc transporter 3 (ZnT3) and vesicular zinc in central nervous system function. Neurosci. Biobehav. Rev., vol. 80, pp. 329-350.
68. Yamasaki S., Sakata-Sogawa K., Hasegawa A., Suzuki T., Kabu K. (2007) Zinc is a novel intracellular second messenger. J. Cell Biol., vol. 177, pp. 637-645.
69. Corona C., Masciopinto F., Silvestri E., Viscovo A.D., Lattanzio R. (2010) Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunction. Cell Death Dis., vol. 1: e91. doi: 10.1038/cddis.2010.73.
70. Ikram M.A., Brusselle G.G.O., Murad S.D., van Duijn C.M., Franco O.H. (2017) The Rotterdam Study: 2018 update on objectives, design and main results. Eur. J. Epidemiol., vol 32, pp. 807-850.
71. Mezzaroba L., Alfieri D.F., Colado Simвo A.N. (2019) The role of zinc, copper, manganese and iron in neurodegenerative diseases. Neurotoxicology, vol. 74, pp. 230-241.
72. Melzer T.M., Manosso L.M., Yau S.Y. (2021) In Pursuit of Healthy Aging: Effects of Nutrition on Brain Function. International journal of molecular sciences, vol. 22, no 9, p. 5026.
73. Guzun O.V., Khramenko N.I., Slobodianyk S.B. (2018) Efficacy of complex neuroprotection in glaucomatous optic neuropathy. J.ophthalmol. (Ukraine), no 5, pp. 32-38.
74. Fogagnolo P., Melardi E., Tranchina L. (2020) Topical citicoline and vitamin B12 versus placebo in the treatment of diabetes-related corneal nerve damage: A randomized double-blind controlled trial. BMC Ophthalmol., vol. 20, p. 315.
75. Synoradzki K., Grieb P. (2019) Citicoline: A Superior Form of Choline? Nutrients, vol. 11, no 7, p. 1569.
76. Adhi M., Duker J.S. (2013) Optical coherence tomography - current and future applications. CurrOpin Ophthalmol., vol. 24, pp. 213-221.
77. Adornetto A., Russo R., Parisi V. (2019) Neuroinflammation as a target for glaucoma therapy. Neural Regen Res., vol. 14, no 3, pp. 391-394.
78. Hayreh S.S. (2020) Controversies on neuroprotection therapy in non-arteritic anterior ischaemic optic neuropathy. Br. J. Ophthalmol., vol. 104, pp. 153-156.
79. Hollo G., Sandor N.G., Kothy P. (2021) Influence of painless one-eye blindness on depression, anxiety and quality of life in glaucoma patients with a normal fellow eye. BMC Ophthalmol., vol. 21, no 1, p. 89.
80. Boskovic Z., Milne M.R., Qian L. (2018) Cholinergic basal forebrain neurons regulate fear extinction consolidation through p75 neurotrophin receptor signaling. TranslPsychiatry, vol. 8, no 1, p. 199.
81. Kumar A., Rinwa P., Kaur G. (2013) Stress: Neurobiology, consequences and management. J Pharm Bioallied Sci, vol. 5, pp. 91-97.
82. Naufal F., Gajwani P., Medina R. (2021) Knowledge of patient emotional health status: impact on clinical care in glaucoma and retinal services. BMJ Open Ophthalmol., vol. 6, no 1, e000640.
83. Fioravanti M., Yanagi M. (2015) Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database SystRev. Available at: 10.1002/14651858.CD000269.pub3. (accessed 18 Apr 2005).
84. Bruce S.E., Werner K., Preston B.F. (2014) Improvements in concentration, working memory and sustained attention following consumption of a natural citicoline-caffeine beverage. Int. J. Food Sci. Nutr., vol. 65, pp. 1003-1007.
85. Tardy A.L., Pouteau E., Marquez D. (2020) Vitamins and Minerals for Energy, Fatigue and Cognition: A Narrative Review of the Biochemical and Clinical Evidence. Nutrients, vol. 12, no 1, p. 228.
86. Rossato M.S., Brilli E., Ferri N. (2021) Observational study on the benefit of a nutritional supplement, supporting immune function and energy metabolism, on chronic fatigue associated with the SARS-CoV-2 post-infection progress. Clinical Nutrition Espen, Advance online publication. Available at: https://doi.org/10.10167j.clnesp.2021.08.031
87. McGlade E. (2012) Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women. Food and Nutrition Sciences, vol. 3, no 6, pp. 769-773. Available at: https://www.researchgate.net/ journal/2157-944X
88. McGlade E., Agoston A.M., DiMuzio J. (2015) The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males. J. Atten. Disord., vol. 23, pp. 121-134.
89. Al-Kuraishy H.M., Al-Gareeb A.I. (2020) Citicoline Improves Human Vigilance and Visual Working Memory: The Role of Neuronal Activation and Oxidative Stress. Basic Clin Neurosci., vol. 11, no 4, pp. 423-432.
90. Petkov V.D., Stancheva S.L., Tocuschieva L. (1990) Changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine (experim. on rats). Gen. Pharmacol. Vasc. Syst., vol. 21, pp. 71-75.
91. Grieb P., Rejdak R. (2002) Pharmacodynamics of citicoline relevant to the treatment of glaucoma. J. Neurosci. Res., vol. 67, pp. 143-148.
92. Jьnemann A.G.M., Grieb P., Rejdak R. (2021) Bedeutung von Citicolin bei der Glaukomerkrankung [The role of citicoline in glaucoma]. Ophthalmologe., vol. 118, no 5, pp. 439-448.